Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16
Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16
复制标题
DOI：
10.1371/journal.pone.0237938
复制
发表时间：
2020-09-02
期刊：
影响因子：
3.7
通讯作者：
Messer, Karen
中科院分区：
文献类型：
--
作者：
Pierce, John P.;Benmarhnia, Tarik;Messer, Karen
更多的吸烟者报告使用电子烟来帮助他们戒烟，而不是FDA批准的药物治疗。目的评估电子烟与未来戒烟和烟草使用的关联。设计美国样本的队列研究，每年随访。（年龄18岁以上）在第1波确定的每日吸烟者（W1; 2013-14），在W2之前报告了戒烟尝试并完成了W3（n = 2443）.暴露使用电子烟、药物治疗（包括尼古丁替代疗法），或末次戒烟尝试（LQA）无产品，以及W2时当前每日电子烟使用情况。分析使用不同方法戒烟的组的倾向评分匹配（PSM）。结果指标12 +在W3时戒烟和所有烟草（包括电子烟）。在W3的30天以上的禁欲是次要outcome.ResultsAmong每日吸烟者与LQA，23.5%使用电子烟，19.3%只使用药物治疗（包括NRT）和57.2%不使用产品。在W3时，每组中戒烟12个月以上的比例相似，均为10%。电子烟组中有一半的戒烟者在W3时使用电子烟。在W3时，不同的戒烟方法具有统计学上相当的12个月以上戒烟率（电子烟与无产品：风险差异（RD）= 0.01，95% CI：-0.04至0.06;电子烟与药物治疗：RD = 0.02，95% CI：-0.04至0.09）。同样，W2的每日电子烟使用者没有显示出比可比的非电子烟使用者更好的戒烟益处，这一发现对敏感性分析是稳健的。在W3戒烟30天以上的产品也是相似的。LimitationsThe频率的电子烟使用LQA期间没有评估，也不可能评估从LQA的持续abstinence.ConclusionAmong US daily smokers who quit cigarettes in 2014-15，使用电子烟在尝试相比，批准的戒烟援助或没有产品显示出类似的戒烟率1-2年后。
BackgroundMore smokers report using e-cigarettes to help them quit than FDA-approved pharmacotherapy.ObjectiveTo assess the association of e-cigarettes with future abstinence from cigarette and tobacco use.DesignCohort study of US sample, with annual follow-up.ParticipantsUS adult (ages 18+) daily cigarette smokers identified at Wave 1 (W1; 2013-14) of the PATH Study, who reported a quit attempt before W2 and completed W3 (n = 2443).ExposuresUse of e-cigarettes, pharmacotherapy (including nicotine replacement therapy), or no product for last quit attempt (LQA), and current daily e-cigarette use at W2.AnalysisPropensity score matching (PSM) of groups using different methods to quit.Outcome measures12+ months abstinence at W3 from cigarettes and from all tobacco (including e-cigarettes). 30+ days abstinence at W3 was a secondary outcome.ResultsAmong daily smokers with an LQA, 23.5% used e-cigarettes, 19.3% used pharmacotherapy only (including NRT) and 57.2% used no product. Cigarette abstinence for 12+ months at W3 was similar to 10% in each group. Half of the cigarette abstainers in the e-cigarette group were using e-cigarettes at W3. Different methods to help quitting had statistically comparable 12+ month cigarette abstinence at W3 (e-cigarettes vs no product: Risk Difference (RD) = 0.01, 95% CI: -0.04 to 0.06; e-cigarettes vs pharmacotherapy: RD = 0.02, 95% CI:-0.04 to 0.09). Likewise, daily e-cigarette users at W2 did not show a cessation benefit over comparable no-e-cigarette users and this finding was robust to sensitivity analyses. Abstinence for 30+ days at W3 was also similar across products.LimitationsThe frequency of e-cigarette use during the LQA was not assessed, nor was it possible to assess continuous abstinence from the LQA.ConclusionAmong US daily smokers who quit cigarettes in 2014-15, use of e-cigarettes in that attempt compared to approved cessation aids or no products showed similar abstinence rates 1-2 years later.